Overcoming heparin limitations in high-risk percutaneous coronary intervention: the alternative strategy-- replacing heparin with bivalirudin.
Henry
Timothy D
TD
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
D015906:Angioplasty, Balloon, Coronary; D003131:Combined Modality Therapy; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D005343:Fibrinolytic Agents; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin